This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Synergy Pharmaceuticals And Fox Chase Cancer Center Presentation At 2011 ACG Meeting Highlights Potential Of GC-C Agonists To Delay Progression Of Colitis Into Colon Cancer

Stocks in this article: SGYP

Synergy Pharmaceuticals, Inc. (OTC QB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that poster P409 presented at the upcoming 2011 annual scientific meeting of the American College of Gastroenterology highlights the potential use of guanylate cyclase-C agonists to delay progression of colitis into colon cancer. Poster P409 was selected as an “ACG Presidential Award Winning Poster”, a recognition given to the most highly ranked abstracts selected for poster sessions in each category. The work reported in poster P409 was a collaborative effort between Synergy scientists and the scientists from Fox Chase Cancer Center, Philadelphia, Drs. Margie Clapper, Wen-Chi Chang and Harry Cooper.

It is well known that patients with both ulcerative colitis (UC) and Crohn’s disease (CD) are at an increased risk of developing colorectal cancer (CRC). A contributing factor to this increased risk appears to be persistent inflammation of the colon.

“We believe that the therapeutic application of GC-C agonists to ameliorate GI inflammation has the potential to delay progression into colon cancer, providing an innovative approach to the treatment of GI inflammatory diseases and prevention of colon cancer,” said Dr. Kunwar Shailubhai, Chief Scientific Officer of Synergy Pharmaceuticals. “Our continued research efforts are focused on exploring GC-C agonists as orally safe drugs to treat GI inflammation and also control its progression to colon cancer.”

These findings represent a significant breakthrough in the clinical care of patients with inflammatory bowel disease, according to Dr. Margie Clapper, Co-Leader of the Cancer Prevention and Control Program at Fox Chase Cancer Center. Intervention with GC-C agonists early in the disease process is expected to block the formation of colon tumors as well as circumvent the need for hundreds of biopsies and, in some cases, major surgery.

The date and time for the presentation are:

Monday October 31, 10:30 am to 4:30 pm

Poster P409: Guanylate Cyclase C Agonists as a New Class of Drug Candidates to Delay Progression of Colitis to Colonic Tumors in Apc Min/+ Mice.

Kunwar Shailubhai 1,2 , Wen-Chi Chang 3 , Shet Masih 2 , Harry S. Cooper 3 , Margie L. Clapper

1 Synergy Pharmaceuticals, Doylestown, PA, 2 Institute of Hepatitis Virus Research, Doylestown, PA, and 3 Fox Chase Cancer Center, Philadelphia, PA, USA.

About Ulcerative Colitis

More than 500,000 Americans are afflicted with ulcerative colitis, a type of IBD that causes chronic inflammation of the colon. Along with Crohn's disease, the other major form of IBD, ulcerative colitis is painful and debilitating, and can lead to other serious and life-threatening complications such as increased incidence of colon cancer. There is currently no medical cure for ulcerative colitis. A considerable medical need exists for the control and treatment of ulcerative colitis.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,677.90 +216.58 1.32%
S&P 500 1,950.82 +23.71 1.23%
NASDAQ 4,452.7920 +69.9450 1.60%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs